A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT06859424)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years to 66 Years
🧪 Interventions in This Study
- Conditioning Regimen A (DRUG)
- Conditioning Regimen B (DRUG)
- Conditioning Regimen C (DRUG)
- Conditioning Regimen D (DRUG)
- Conditioning Regimen E (DRUG)
- PTCy (50 mg/kg D3, D4) (DRUG)
- PTCy (25 mg/kg D3, D4) (DRUG)
- Post-transplant Tacrolimus (DRUG)
- Post-transplant Mycophenolate mofetil (DRUG)
- Post-transplant Abatacept (DRUG)
- Post-transplant Ruxolitinib (DRUG)
- Supportive Care: Growth Factors (DRUG)
- Supportive Care: Seizure prophylaxis (DRUG)
- Supportive Care: Prophylaxis against infections (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- City of Hope — Duarte, California
- Stanford — Palo Alto, California
- University of Miami — Miami, Florida
- University of Kansas Medical Center — Westwood, Kansas
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Memorial Sloan Kettering — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Oregon Health & Science University — Portland, Oregon
- MD Anderson — Houston, Texas
- University of Virginia — Charlottesville, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (763) 406-8087
Email: accelerate@nmdp.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML (Acute Myelogenous Leukemia)
Explore by condition: All AML (Acute Myelogenous Leukemia) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.